Acetylcysteine, anticholinergics
Dangerous secretory congestion due to the reduced cough reflex and the inhibitor of the bronchial secretions. Co-administration is not recommended
Aclidinium [1], anticholinergics ---> SmPC of [1] of EMA
Co-administration of aclidinium bromide with other anticholinergic-containing medicinal products has not been studied and is not recommended.
Aclidinium/formoterol [1], anticholinergics ---> SmPC of [1] of EMA
Co-administration of aclidinium/formoterol with other anticholinergic and/or long beta2-adrenergic agonist containing medicinal products has not been studied and is not recommended.
Adrenaline, anticholinergics
The effects of adrenaline may be potentiated by parasympatholytics
Alcohol, anticholinergics
Anticholinergic drugs may enhance the depressive effect of alcohol on the central nervous system
Aliskiren/amlodipine/hydrochlorothiazide [1], anticholinergics ---> SmPC of [1] of EMA
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.
Aliskiren/hydrochlorothiazide [1], anticholinergics ---> SmPC of [1] of EMA
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.
Alizapride, anticholinergics
Anticholinergic agents may weaken the alizapride effect.
Amantadine [1], anticholinergics ---> SmPC of [1] of eMC
Concurrent administration of amantadine and anticholinergic agents may increase confusion, hallucinations, nightmares, gastro-intestinal disturbances, or other atropine-like side effects
Amifampridine [1], anticholinergics ---> SmPC of [1] of EMA
The concomitant use of amifampridine and medicinal products with atropinic effects may reduce the effect of both active substances
Amitriptyline [1], anticholinergics ---> SmPC of [1] of eMC
Excessive anticholinergic effects may occur when tricyclic antidepressants are combined with anticholinergic drugs.
Amitriptylinoxide, anticholinergics
The combination of amitriptylinoxide with anticholinergic agents may potentiate the central and peripheral effects (especially delirium)
Amlodipine/valsartan/hydrochlorothiazide [1], anticholinergics ---> SmPC of [1] of EMA
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.
Antacids, anticholinergics
The co-administration may decrease the absorption of anticholinergic agent. The anticholinergic should be administered at least 1 hour before antacid
Anticholinergic antiparkinsonian agents, lisuride
Risk of increased neuropsychiatric disorders. Co-administration is not recommended
Anticholinergic antiparkinsonian agents, oxybutynine [2] ---> SmPC of [2] of EMA
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity
Anticholinergics [1], cyclopentolate ---> SmPC of [1] of eMC
The effects of antimuscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties
Anticholinergics [1], procarbazine ---> SmPC of [1] of eMC
Procarbazine may enhance the effect of drugs with anticholinergic effects
Anticholinergics, anticholinergics
Additive anticholinergic effect
Anticholinergics, anticholinesterase
The therapeutic effects may be reduced due to antagonism.
Anticholinergics, antihistamines
Anticholinergic drugs associated with antihistaminics may have an additive antimuscarinic effect, which increases the risk of worsening glaucoma or urinary retention.
Anticholinergics, atropine [2] ---> SmPC of [2] of eMC
Combination of atropine with other drugs with anticholinergic activity may increase the risk of atropinic adverse effects (urinary retention, constipation, dry mouth).
Anticholinergics, beclometasone/formoterol/glycopyrronium [2] ---> SmPC of [2] of EMA
Due to the anticholinergic effect of glycopyrronium, the long-term co-administration of Trimbow with other anticholinergic-containing medicinal products is not recommended
Anticholinergics, bendroflumethiazide
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.
Anticholinergics, beta-adrenergic agonists [2] ---> SmPC of [2] of EMA
Concomitant use of beta adrenergic medicinal products and anticholinergic medicinal products can have a potentially additive bronchodilating effect.
Anticholinergics, bethanechol
Anticholinergic drugs decrease the effect of bethanechol
Anticholinergics, biperiden
The combination of biperiden with other anticholinergic medicinal products may enhance the central and peripheral adverse reactions
Anticholinergics, bornaprine
The co-administration of bornaprine with other anticholinergic drugs may enhance the central and peripheral adverse effects
Anticholinergics, breast-feeding
Contraindicated
Anticholinergics, bromhexine
Bronchial secretion inhibitors may antagonize the effects of bromhexine
Anticholinergics, bromperidol
The co-administration may enhance the anticholinergic effects
Anticholinergics, brovanexine
The concomitant use of brovanexine and drugs that inhibit the bronchial secretions is not recommended
Anticholinergics, budesonide/formoterol [2] ---> SmPC of [2] of EMA
Concomitant use of beta adrenergic medicinal products and anticholinergic medicinal products can have a potentially additive bronchodilating effect.
Anticholinergics, butylscopolamine [2] ---> SmPC of [2] of eMC
The anticholinergic effect may be intensified by hyoscine butylbromide
Anticholinergics, butyrophenones
Additive anticholinergic effect
Anticholinergics, calcium
Decreased absorption of anticholinergic agent. It is recommended to administer the two substances at least 1-2 hours apart.
Anticholinergics, calcium acetate [2] ---> SmPC of [2] of eMC
Decreased absorption of anticholinergic agent. It is recommended to administer the two substances at least 1-2 hours apart.
Anticholinergics, carbocisteine
The concomitant use of carbocisteine and drugs that inhibit the bronchial secretions is not recommended
Anticholinergics, chloral hydrate
Delirium may occur, especially in the elderly, particularly when used in conjunction with anticholinergics.
Anticholinergics, chlorpromazine [2] ---> SmPC of [2] of eMC
The co-administration causes addition of atropinic adverse effects e. g. retention of urine, dry mouth, obstipation
Anticholinergics, chlorprothixene
The co-administration of chlorprothixene with anticholinergic drugs may enhance the anticholinergic effects
Anticholinergics, chlortalidone ---> SmPC of [losartan/hydrochlorothiazide] of eMC
The anticholinergic increases the bioavailability to thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Anticholinergics, cholinergic agents
The therapeutic effects may be reduced due to antagonism.
Anticholinergics, cinitapride
Decreased effects of cinitapride on the digestive canal
Anticholinergics, cisapride
Anticholinergic drugs may antagonise the gastrointestinal effects of prokinetic drugs
Anticholinergics, clebopride
Decreased effects of clebopride on the digestive canal
Anticholinergics, clenbuterol
The co-administration may increase the effect of clenbuterol
Anticholinergics, clomipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Anticholinergics, cloperastine
Antihistaminics enhance the anticholinergic effect
Anticholinergics, cloprednol
Additional increase in the intraocular pressure
Anticholinergics, clozapine [2] ---> SmPC of [2] of eMC
Because of the possibility of additive effects, caution is essential in the concomitant administration of clozapine with substances possessing anticholinergic effects
Anticholinergics, codeine [2] ---> SmPC of [2] of eMC
Risk of severe constipation which may lead to paralytic ileus, and /or urinary retention
Anticholinergics, cyclizine
Because of its anticholinergic activity cyclizine may enhance the side-effects of other anticholinergic drugs.
Anticholinergics, deflazacort
Additional increase in the intraocular pressure
Anticholinergics, desipramine
Tricyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Anticholinergics, dexamethasone
Additional increase in the intraocular pressure
Anticholinergics, dexchlorpheniramine
Additive anticholinergic effects
Anticholinergics, dextromethorphan
The anticholinergic effects may be enhanced
Anticholinergics, dextromethorphan/quinidine [2] ---> SmPC of [2] of EMA
Patients should be monitored for worsening clinical condition in myasthenia gravis and other conditions that may be adversely affected by anticholinergic effects.
Anticholinergics, dimenhydrinate
The co-administration of dimenhydrinate with other anticholinergic drugs may enhance or prolong the anticholinergic effect
Anticholinergics, dimethindene
Anticholinergic drugs associated with antihistaminics may have an additive antimuscarinic effect, which increases the risk of worsening glaucoma or urinary retention.
Anticholinergics, diphenhydramine [2] ---> SmPC of [2] of eMC
As diphenhydramine has some antimuscarinic activity, the effects of anticholinergic drugs may be potentiated therefore medical advice should be sought before taking diphenhydramine with such medicines.
Anticholinergics, disopyramide [2] ---> SmPC of [2] of eMC
Atropine and other anticholinergic drugs, including phenothiazines, may potentiate the atropine-like effects of disopyramide.
Anticholinergics, distigmine
The co-administration may antagonize the muscarinic effects of distigmine
Anticholinergics, dixyrazine
Dixyrazine enhances the anticholinergic effect
Anticholinergics, donepezil
Donepezil hydrochloride has the potential to interfere with medications having anticholinergic activity.
Anticholinergics, donepezil [2] ---> SmPC of [2] of eMC
Donepezil hydrochloride has the potential to interfere with medications having anticholinergic activity.
Anticholinergics, dopamine antagonists
Mutual weakening of effect on gastrointestinal motility
Anticholinergics, doxepin
The co-administration may enhance the anticholinergic effect
Anticholinergics, doxylamine
The combination of doxylamine with other anticholinergic medicinal products may enhance the anticholinergic effects
Anticholinergics, eluxadoline [2] ---> SmPC of [2] of EMA
Chronic use of loperamide with eluxadoline should be avoided as this may increase the risk of constipation. The use of eluxadoline with other medicinal products that may cause constipation (for example anticholinergics, opioids) should also be avoided.
Anticholinergics, epinephrine
The effects of adrenaline may be potentiated by parasympatholytics
Anticholinergics, eserine
The co-administration may abolish the anticholinergic effect
Anticholinergics, fenoterol
The co-administration may increase the bronchodilator effect
Anticholinergics, fesoterodine [2] ---> SmPC of [2] of EMA
Caution should be exercised in coadministration of fesoterodine with other antimuscarinics and medicinal products with anticholinergic properties as this may lead to more pronounced therapeutic-and side-effects
Anticholinergics, flavoxate
Increased anticholinergic effect
Anticholinergics, fluocortolone
Additional increase in the intraocular pressure
Anticholinergics, flupentixol
The anticholinergic effects of other drugs with anticholinergic properties may be increased.
Anticholinergics, fluphenazine [2] ---> SmPC of [2] of eMC
Anticholinergic effects may be enhanced by other anticholinergic drugs.
Anticholinergics, fluspirilene
The co-administration of fluspirilene with anticholinergic drugs may enhance the anticholinergic effects
Anticholinergics, formoterol ---> SmPC of [budesonide/formoterol] of EMA
Concomitant use of beta adrenergic medicinal products and anticholinergic medicinal products can have a potentially additive bronchodilating effect.
Anticholinergics, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA
Co-administration of this medicinal product is not recommended as it may potentiate known inhaled muscarinic antagonist or beta2-adrenergic agonist adverse reactions
Anticholinergics, galantamine [2] ---> SmPC of [2] of eMC
Galantamine has the potential to antagonise the effect of anticholinergic medicinal products. Should anticholinergic medicinal products such as atropine be abruptly stopped there is a potential risk that galantamine's effect could be exace
Anticholinergics, glucocorticoids
An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs.
Anticholinergics, glycopyrrolate
Administration of anticholinergic agents during inhalation anaesthesia can result in ventricular arrhythmias
Anticholinergics, glycopyrronium [2] ---> SmPC of [2] of EMA
The co-administration of glycopyrronium with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Anticholinergics, haloperidol
The co-administration may enhance the anticholinergic effect
Anticholinergics, homatropine
The co-administration may enhance the anticholinergic effect
Anticholinergics, hydrochlorothiazide ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA
The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents, apparently due to a decrease in gastrointestinal motility and the stomach emptying rate.
Anticholinergics, hydrocortisone
Additional increase in the intraocular pressure
Anticholinergics, hydrotalcite
The co-administration of hydrotalcite with other drugs may decrease the absorption of these drugs. It is recommended to separate the times of administration by at least 1-2 hours
Anticholinergics, hydroxyzine [2] ---> SmPC of [2] of eMC
Additive anticholinergic effects may occur if hydroxyzine is administered concomitantly with other anticholinergic agents
Anticholinergics, IMAOs
Monoamine oxidase inhibitors can interact with concurrently administered anticholinergic agents. This can cause dry mouth, blurred vision, urinary hesitancy, urinary retention and constipation.
Anticholinergics, imipramine [2] ---> SmPC of [2] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Anticholinergics, indacaterol/glycopyrronium [2] ---> SmPC of [2] of EMA
The co-administration of indacaterol/glycopyrronium with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended
Anticholinergics, ipratropium
Ipratropium may enhance the anticholinergic effects of other drugs
Anticholinergics, isocarboxazid
Concurrent administration of isocarboxazid with anticholinergic drugs may lead to potentiation of their effects.
Anticholinergics, ketamine
The anticholinergic effects may be enhanced
Anticholinergics, ketoconazole ---> SmPC of [procyclidine] of eMC
Anticholinergics may reduce the absorption of ketoconazole.
Anticholinergics, lactulose
Weakening of the laxative effect
Anticholinergics, laxatives
Weakening of the laxative effect
Anticholinergics, levodopa
Anticholinergics may reduce the efficacy of levodopa by increasing gastric emptying time
Anticholinergics, levodopa ---> SmPC of [levodopa/carbidopa] of EMA
Concurrent use can cause a worsening of involuntary motor disorders. Anticholinergic medicinal products may impair the effect of levodopa, due to a delayed absorption. A dose adjustment of levodopa may be required.
Anticholinergics, levodopa/benserazide [2] ---> SmPC of [2] of eMC
Combination of levodopa/benserazide with other anti-Parkinsonian agents is permissible, though both the desired and undesired effects of treatment may be intensified.
Anticholinergics, levodopa/carbidopa [2] ---> SmPC of [2] of EMA
Concurrent use can cause a worsening of involuntary motor disorders. Anticholinergic medicinal products may impair the effect of levodopa, due to a delayed absorption. A dose adjustment of levodopa may be required.
Anticholinergics, levomepromazine [2] ---> SmPC of [2] of eMC
The anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.
Anticholinergics, levosulpiride
The effects of levosulpiride on the gastric motility may be antagonized by anticholinergic drugs
Anticholinergics, lofepramine
Lofepramine may potentiate the effects of anticholinergic drugs on the central nervous system, eye, bowel and bladder.
Anticholinergics, loperamide [2] ---> SmPC of [2] of eMC
It is expected that drugs with similar pharmacological properties may potentiate loperamide's effect
Anticholinergics, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
The anticholinergic increases the bioavailability to thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Anticholinergics, loteprednol
The low potential of ocular loteprednol etabonate eye drops to increase the intraocular pressure may be adversely affected by systemically administered medicinal products with anticholinergic activity.
Anticholinergics, loxapine [2] ---> SmPC of [2] of EMA
Because of anticholinergic action, loxapine should be used cautiously in patients with glaucoma or a tendency to urinary retention, particularly with concomitant administration of anticholinergic-type antiparkinson medicinal product.
Anticholinergics, magnesium hydroxide
The magnesium hydroxide may decrease the absorption of anticholinergic. Separate administration by 2-3 hours
Anticholinergics, maprotiline
The combination of maprotiline with anticholinergic agents may potentiate the central and peripheral effects (especially delirium)
Anticholinergics, melitracen
Tricyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Anticholinergics, melperone
The co-administration may increase the anticholinergic effects
Anticholinergics, memantin [2] ---> SmPC of [2] of EMA
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Anticholinergics, mequitazine
The co-administration of mequitazine and other anticholinergic drugs may enhance the anticholinergic effects of mequitazine
Anticholinergics, methocarbamol
The effects of anticholinergics may be potentiated by methocarbamol.
Anticholinergics, methylprednisolone [2] ---> SmPC of [2] of eMC
An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs.
Anticholinergics, metoclopramide [2] ---> SmPC of [2] of eMC
The action of metoclopramide on the gastrointestinal tract is antagonized by anticholinergics
Anticholinergics, morphine [2] ---> SmPC of [2] of eMC
Medicinal products that block the action of acetylcholine may interact with morphine sulphate to potentiate anticholinergic adverse events.
Anticholinergics, N-methyl-D-aspartate antagonists ---> SmPC of [memantin] of EMA
The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Anticholinergics, nefopam
Increased risk of antimuscarinic side effects when antimuscarinics are given with nefopam.
Anticholinergics, neuroleptics
The anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.
Anticholinergics, nitroglycerine [2] ---> SmPC of [2] of eMC
There is a potential for drugs that cause dry mouth (eg anticholinergic, antimuscarinics, tricyclic antidepressants) to reduce the effectiveness of sublingual nitrates.
Anticholinergics, noradrenaline
The use of noradrenaline with parasympatholytic drugs is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Anticholinergics, norepinephrine
The use of noradrenaline with parasympatholytic drugs is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Anticholinergics, nortriptyline [2] ---> SmPC of [2] of eMC
Supervision and adjustment of dosage may be required when nortriptyline is used with other anticholinergic drugs.
Anticholinergics, opipramol
Tricyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Anticholinergics, orciprenaline
Concomitant treatment with anticholinergic agents may enhance the effect of orciprenaline
Anticholinergics, organic nitrates ---> SmPC of [nitroglycerine] of eMC
There is a potential for drugs that cause dry mouth to reduce the effectiveness of sublingual nitrates.
Anticholinergics, orphenadrine
Concomitant use of other antimuscarinic drugs can lead to an increase in side effects such as dry mouth and urine retention.
Anticholinergics, oxomemazine
Enhancement of central anticholinergic effect
Anticholinergics, oxybutynine [2] ---> SmPC of [2] of EMA
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity
Anticholinergics, oxycodone [2] ---> SmPC of [2] of eMC
Anticholinergics can enhance the anticholinergic undesirable effects of oxycodone (such as constipation, dry mouth or micturition disorders).
Anticholinergics, parasympathomimetics
Drugs with anticholinergic properties may antagonise the effect of parasympathetic agents.
Anticholinergics, perazine
The combination of perazine with anticholinergic drugs may additively enhance the anticholinergic effects
Anticholinergics, periciazine
Increased anticholinergic effects (risk of paralytic ileus and hyperthermia)
Anticholinergics, perphenazine
The combination of perphenazine with anticholinergic drugs may additively enhance the anticholinergic effects
Anticholinergics, pethidine [2] ---> SmPC of [2] of eMC
Use of pethidine concomitantly with anticholinergics may result in neurotoxicity in patients with renal failure, cancer, and sickle cell anaemia.
Anticholinergics, phenothiazines
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Anticholinergics, phenothiazines
The combination may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Anticholinergics, physostigmine
The co-administration may abolish the anticholinergic effect
Anticholinergics, pilocarpine [2] ---> SmPC of [2] of eMC
Pilocarpine might antagonise the anticholinergic effects of other drugs used concomitantly
Anticholinergics, pinaverium
Co-administration of an anticholinergic drug may enhance spasmolysis.
Anticholinergics, pipotiazine [2] ---> SmPC of [2] of eMC
The mild anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc.
Anticholinergics, pirenzepine
Possible enhancement of anticholinergic effect
Anticholinergics, potassium chloride
The ulcerative effects of solid oral dosage forms of potassium chloride may be enhanced by the anticholinergic
Anticholinergics, prednisolone
The co-administration may increase an existing intraocular tension
Anticholinergics, prednisone [2] ---> SmPC of [2] of eMC
The concurrent use may result in additional increases in intraocular pressure.
Anticholinergics, pregnancy
Strict indication
Anticholinergics, prifinium
The co-administration may enhance the anticholinergic effects
Anticholinergics, procainamide
The co-administration may cause additive anticholinergic effects on the AV node conduction
Anticholinergics, procyclidine [2] ---> SmPC of [2] of eMC
Drugs with anticholinergic properties may increase the anticholinergic action
Anticholinergics, prokinetics
Anticholinergic drugs may antagonise the gastrointestinal effects of prokinetic drugs
Anticholinergics, promazine
Undesirable anticholinergic effects can be enhanced by anti-parkinson or other anticholinergic drugs
Anticholinergics, promethazine [2] ---> SmPC of [2] of eMC
Promethazine will enhance the action of any anticholinergic agent
Anticholinergics, propafenone
Enhancement of anticholinergic effect
Anticholinergics, propiverine [2] ---> SmPC of [2] of eMC
Increased effects of propiverine due to concomitant medication with anticholinergics
Anticholinergics, propofol
The co-administration may prolong the anesthesia duration and decrease the respiratory rate
Anticholinergics, prucalopride
Possible decreased effects of prucalopride
Anticholinergics, pseudoephedrine [2] ---> SmPC of [2] of eMC
There may be increased risk of arrhythmias if pseudoephedrine is given to patients receiving anticholinergic drugs
Anticholinergics, quinidine ---> SmPC of [dextromethorphan/quinidine] of EMA
Patients should be monitored for worsening clinical condition in myasthenia gravis and other conditions that may be adversely affected by anticholinergic effects.
Anticholinergics, reproterol
Enhancement of effects and adverse effects (e.g. tachycardia, arrhythmia)
Anticholinergics, rifampicin
The anticholinergic agent decreases the absorption of rifampicin. Rifampicin should be given at least 1 hour before the anticholinergic agent
Anticholinergics, rivastigmine [2] ---> SmPC of [2] of EMA
Rivastigmine might interfere with the activity of the anticholinergic medicinal product
Anticholinergics, salmeterol
Possible additive effect
Anticholinergics, scopolamine
Scopolamine may enhance the anticholinergic effect
Anticholinergics, secretin
Decreased secretin effect
Anticholinergics, selegiline [2] ---> SmPC of [2] of eMC
Concomitant administration of selegiline and anticholinergic drugs can lead to an increased occurrence of side-effects.
Anticholinergics, solifenacin [2] ---> SmPC of [2] of eMC
Comedication with other anticholinergic drugs may result in more pronounced therapeutic and undesirable effects. Between solifenacin and other anticholinergic should be an interval of at least 1 week
Anticholinergics, terbutaline
The co-administration may enhance the antiobstruktive effect of terbutaline
Anticholinergics, tetracyclic antidepressant
Tetracyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Anticholinergics, thiazides
Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Anticholinergics, thiazides ---> SmPC of [losartan/hydrochlorothiazide] of eMC
The anticholinergic increases the bioavailability to thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Anticholinergics, thioridazine
The combination with phenothiazines may exacerbate anticholinergic side effects, including atropine-like psychoses, paralytic ileus, and hyperpyretic effects until heat stroke
Anticholinergics, thioxanthenes
Increased anticholinergic effect
Anticholinergics, tiapride
Anticholinergic agents may weaken the effect of tiapride
Anticholinergics, tiotropium [2] ---> SmPC of [2] of eMC
The co-administration of tiotropium bromide with other anticholinergic-containing drugs has not been studied and is therefore not recommended
Anticholinergics, triamcinolone
Additional increase in the intraocular pressure
Anticholinergics, triamcinolone acetonide
Additional increase in the intraocular pressure
Anticholinergics, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Anticholinergics, trifluoperazine [2] ---> SmPC of [2] of eMC
The anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.
Anticholinergics, trihexyphenidyl
Additive anticholinergic effect
Anticholinergics, trimebutine
Additive anticholinergic effect
Anticholinergics, trimipramine
The co-administration of trimipramine with other anticholinergic drugs may enhance the central and peripheral effects (particularly delirium)
Anticholinergics, tropicamide
Enhancement of anticholinergic effect
Anticholinergics, trospium [2] ---> SmPC of [2] of eMC
Potentiation of the effect of drugs with anticholinergic action
Anticholinergics, umeclidinium [2] ---> SmPC of [2] of EMA
Co-administration of umeclidinium bromide with other long-acting muscarinic antagonists is not recommended as it may potentiate known inhaled muscarinic antagonist adverse reactions.
Anticholinergics, umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA
Co-administration of umeclidinium bromide with other long-acting muscarinic antagonists is not recommended as it may potentiate known inhaled muscarinic antagonist adverse reactions.
Anticholinergics, zonisamide [2] ---> SmPC of [2] of EMA
Caution should be used in adults when Zonegran is prescribed with other medicinal products that predispose patients to heat related disorders; these include carbonic anhydrase inhibitors and medicinal products with anticholinergic activity
Anticholinergics, zotepine
The co-administration may cause a mutual potentiation of effects
Anticholinergics, zuclopenthixol [2] ---> SmPC of [2] of eMC
The anticholinergic effects of other drugs with anticholinergic properties may be increased.